Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

@article{Mulligan2020PhaseIS,
  title={Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults},
  author={Mark J. Mulligan and Kirsten E. Lyke and Nicholas R E Kitchin and Judith Absalon and Alejandra C Gurtman and Stephen Lockhart and Kathleen M. Neuzil and Vanessa N Raabe and Ruth Bailey and Kena A. Swanson and Ping Li and Kenneth J. Koury and Warren Vincent Kalina and David Cooper and Camila R Fontes-Garfias and Pei-Yong Shi and {\"O}zlem T{\"u}reci and Kristin R Tompkins and Edward E Walsh and Robert W. Frenck and Ann R. Falsey and Philip R. Dormitzer and William C. Gruber and Uğur Şahin and Kathrin U. Jansen},
  journal={Nature},
  year={2020},
  pages={1-5}
}
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 , a pandemic. With rapidly accumulating numbers of cases and deaths reported globally 2 , a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among… 
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
TLDR
Vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19.
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
TLDR
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate, and systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in thoseWho received the high dose, while reactogenicity was lower after the second dose.
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
TLDR
At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum, and the addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response.
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
TLDR
The primary efficacy endpoint for a random placebo-controlled clinical trial of a COVID-19 vaccine to be approved by US FDA should confer at least 50% protection against CO VID-19.
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
TLDR
The three-dose regimen strategy of the mRNA-RBD vaccine proposed in the present study appears to be a promising reference for the development of mRNA vaccines targeting SARS-CoV-2 variants.
Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
TLDR
All tested doses of PTX-COVID19-B were safe, well-tolerated, and provided a strong immunogenicity response, and the 40-gdose showed fewer adverse reactions than the 100-g dose, supporting further investigation of the 40,g dose.
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
TLDR
Preliminary safety, tolerability and immunogenicity data from an ongoing single-center, parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants suggest it has an acceptable safety profile and produces high levels of humoral and T cell responses in an Asian population.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
TLDR
BNT162b2 elicits an adaptive humoral and poly-specific cellular immune response against epitopes conserved in a broad range of variants at well tolerated doses, and pMHC multimer technology identified several BNT 162b2-induced epitopes that were presented by frequent MHC alleles and conserving in mutant strains.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
TLDR
Additional safety and immunogenicity data from the US Phase 1 trial supported selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.
Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine
TLDR
The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
TLDR
It is shown that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell, and monoclonal antibodies isolated here are promising candidates for COVID-19 treatment and prevention.
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
TLDR
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses.
An Infectious cDNA Clone of SARS-CoV-2
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
TLDR
A fluorescence-based SARS-CoV-2 neutralization assay is reported on that detects Sars- CoV- 2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing.
Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020
TLDR
The COVID-19 pandemic continues to be severe, particularly in certain population groups, and the need to build on current efforts to collect and analyze case data, especially among those with underlying health conditions is underscored.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
TLDR
A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19, and demonstrates the speed and robustness of advanced antibody discovery platforms.
...
...